Kailera Therapeutics Cash Flow Statement
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kailera Therapeutics has no annual cash flow statement on file yet, so quarterly figures are shown instead.
Kailera Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Kailera Therapeutics generated -$77.5 million of operating cash flow. That left free cash flow of -$77.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Kailera Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -111.31M | -78.86M | -28.95M | -17.98M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 101.00K | 101.00K | 62.00K | 63.00K |
| Stock-Based Compensation | 8.34M | 3.94M | 1.63M | 1.52M |
| Change in Working Capital | 11.05M | -453.00K | -4.34M | -2.03M |
| Operating Cash Flow | -77.53M | -68.31M | -26.23M | -18.20M |
| Investing Cash Flow | -571.02M | 22.85M | -74.17M | -54.44M |
| Financing Cash Flow | 667.03M | -2.98M | 100.00M | 0 |
| Net Change in Cash | 18.48M | -48.44M | -403.00K | -72.64M |
| Free Cash Flow | -77.53M | -68.31M | -26.23M | -18.20M |
This table shows 4 quarterly periods of Kailera Therapeutics's cash flow statement, from Q2 2026 back to Q? 2025, across 9 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KLRA's reporting calendar. What is a cash flow statement?